Genmab

	24/4 07:52 af E L	if i am not mistaken this is the data we saw at ASH?
	24/4 07:52 af E L	Blood article : Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN (link)
	24/4 06:49 af bibob	God morgen. :-)
	23/4 21:32 af Solsen	(link) MedWatch på rem
	23/4 21:05 af Bulder	Det drejer sig altså om et af de kinesiske studier (svær covid19), som blev afbrudt forleden pga manglende rekruttering.
	23/4 21:02 af Bulder	The studies are either fully enrolled for the primary analysis or on track to fully enroll in the near future. slut
	23/4 21:01 af Bulder	We understand the available data have been submitted for peer-reviewed publication, which will provide more detailed information from this study in the near future. There are multiple ongoing Phase 3 studies that are designed to provide the additional data needed to determine the potential for remdesivir as a treatment for COVID-19. These studies will help inform whom to treat, when to treat and how long to treat with remdesivir. forts.
	23/4 21:01 af Bulder	Importantly, because this study was terminated early due to low enrollment, it was underpowered to enable statistically meaningful conclusions. As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease. forts.
	23/4 21:00 af Bulder	We regret that the WHO prematurely posted information regarding the study, which has since been removed. The investigators in this study did not provide permission for publication of results. Furthermore, we believe the post included inappropriate characterizations of the study. forts.
	23/4 21:00 af Bulder	(Bloomberg) -- Here is the full text of an emailed statement from Gilead Sciences Inc. after reports that the company’s experimental drug being tested in severe Covid-19 patients failed to show a positive result in a Chinese trial. forts.
	23/4 20:28 af Solsen	Agree on WHO...
	23/4 20:26 af E L	;-)
	23/4 20:25 af GeorgeBest	Hope we will also get facts soon ;-)
	23/4 20:24 af E L	anohter mistake by WHO by the way, not very impressed with this organisation the last few months...
	23/4 20:23 af E L	one should only trade on Genmab rumours from @GeorgeBest ;-)
	23/4 20:21 af E L	so many people that have no clue suddenly think they are experts and judge and trade on rumours.... not an easy market...
	23/4 20:20 af E L	i read it was an article that was not yet peer-reveiwed and immediately removed from their site. i think it is on the chinese trial, which may not the best triel to judge on anyway
	23/4 20:03 af Solsen	GILD has to be quick to report, if WHO knows something.
	23/4 19:26 af Solsen	Svar på det retrospektive skriv fra forleden, der anførte højere dødelighed i HCQ grupperne (link)
	23/4 19:00 af troldmanden	Den kan de da ikke spinde rundt til noget positivt
	23/4 18:54 af E L	GILD back open and recovering most of 7% loss
	23/4 18:53 af E L	[RTRS] - GILEAD WARNED THAT THE DRAFT DOCUMENT POSTED ACCIDENTALLY BY WHO INCLUDED “INAPPROPRIATE CHARACTERISATIONS OF THE STUDY”- FT
	23/4 18:50 af E L	Gilead halted?
	23/4 18:50 af E L	[RTRS] - REMDESIVIR, HAS FLOPPED IN ITS FIRST RANDOMISED CLINICAL TRIAL, ACCORDING TO DRAFT DOCUMENTS PUBLISHED ACCIDENTALLY BY THE WHO - FT

	23/4 18:49 af E L	i am not sure lol, actually the markets tank the minute you write this
	23/4 18:48 af Solsen	Can we use that ?
	23/4 18:48 af Solsen	I have had a dream that JNJ have been doing a calculation ;-)
	23/4 18:46 af Solsen	But what a strory about a girl. Thanks ofa she is alive and hopefully will be in many years.
	23/4 18:45 af E L	;-) your turn GB , give us a bit more on that partner deal rumour ;-)
	23/4 17:59 af GeorgeBest	Keep talking E L ;-)
	23/4 17:27 af E L	(rare disease of the central nervous system)
	23/4 17:27 af E L	Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder (link)
	23/4 17:15 af JKY_VH	Ja det ser godt ud. Vi håber på en god dag i morgen gerne toppet op med en god fredagsnyhed:-)
	23/4 17:04 af Bulder	Så er der kun 52 kr op til lukkerekorden. Og i dag fik vi 51,5. Så i morgen ;-)
	23/4 17:02 af hspinvest	bestemt godkendt ! :-)
	23/4 17:01 af Vitus	Flot luk..
	23/4 16:30 af AaBforever	Tyrene er helt vilde...:-D
	23/4 16:29 af AaBforever	Hu...hej...hvor det går..:-D
	23/4 16:28 af Solsen	Jo 50-60 point om dagen bliver også til noget :-)
	23/4 16:26 af Plimsoller	Det er svært at være negativ i disse dage. Det er også et stykke tid siden vi har set nohope ;-)
	23/4 16:21 af bikube	Og JnJ fortsætter og op over ATH.
	23/4 16:15 af StockBull	Yes now 1652
	23/4 16:15 af E L	haha
	23/4 16:12 af Muldyr	Keep talking E L... :-)
	23/4 16:03 af E L	so with a bit of luck they may find more areas to apply this drug to
	23/4 16:02 af E L	“we see the scleroderma initial study as something that gives us insight into fibrotic diseases more broadly.”
	23/4 16:02 af E L	In hopes of expanding the drug’s label, Horizon will soon launch an exploratory study in patients with diffuse cutaneous scleroderma, an autoimmune disorder in which excess collagen production causes skin thickening over large swathes of the body
	23/4 15:59 af E L	“I’ve had patients crying and hugging me” after receiving Tepezza, adds Wester, who was involved in the drug’s clinical testing. “For those patients who have a good response, it’s really life-altering for them.”
	23/4 15:46 af E L	re Tepezza (teprotumumab) : IGF-1R drugs travel from cancer cradle to Graves’ (link)
	23/4 14:36 af Bulder	Bliver der forresten q&a igen, Helge?